Merck Partners with Array BioPharma and Pierre Fabre to Initiate BRAF-mutant CRC Phase III Trial

Merck KGaA [Newsroom]
Darmstadt, Germany (ots/PRNewswire) - Not intended for UK- or US-based media - BEACON CRC trial will assess efficacy of combination regime Erbitux® (cetuximab), binimetinib and encorafenib in BRAF-mutant metastatic colorectal cancer (mCRC) ... Lesen Sie hier weiter...

Share this post:

Recent Posts

Comments are closed.